Thelansis

Locally Advanced or Metastatic Urothelial Cancer Market Outlook Thelansis’s “Locally Advanced or Metastatic Urothelial Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Locally Advanced or Metastatic Urothelial Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient shar...

  Locally Advanced or Metastatic Urothelial Cancer Market Outlook Thelansis’s “Locally Advanced or Metastatic Urothelial Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Locally Advanced or Metastatic Urothelial Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Locally Advanced or Metastatic Urothelial Cancer Overview Locally advanced or metastatic urothelial cancer (UC), the most common form of bladder cancer, represents an aggressive malignancy with historically poor outcomes. From a biopharma and life science perspective, the treatment paradigm for this disease has undergone a dramatic transformation, moving from ...

 Urothelial Carcinoma (UC), also called Transitional cell carcinoma (TCC), includes cancer in the renal pelvis, ureters, and bladder. The clinical spectrum of TCC in the urinary system can be divided into noninvasive/superficial tumors, invasive, and metastatic lesions. HE4 biomarkers are elevated in the serum of patients diagnosed with TCC in the urinary system regardless of the TNM stage. Urothelial carcinoma (or UCC) accounts for about 90% of all bladder cancers. UC of the urinary bladder confers significant mortality, and patients often require an aggressive therapeutic strategy. Although advanced and metastatic urothelial carcinoma (mUC) of the bladder is a small subset of all urothelial tumors, it accounts for the majority of the disease's rapid mortality. Prior to combination cisplatin-based chemotherapy, median survival in the mUC setting was only 4 to 6 months. While an improvement, relapse and progression are still very common in this disease, and second-line chemotherapi...